Clasificar por
Keyphrases
Psoriasis
72%
Moderate-to-severe Psoriasis
70%
Psoriasis Severity
34%
Area Index
32%
Severity Index
32%
Psoriasis Area
32%
Ustekinumab
29%
Psoriatic Arthritis
28%
Ixekizumab
20%
Psoriasis Treatment
19%
Spain
16%
Interleukin-17 (IL-17)
15%
Secukinumab
14%
Psoriasis Disease
13%
Dermatology Life Quality Index
13%
Clinical Trials
13%
Quality of Life
12%
Etanercept
12%
Dermatologist
12%
Atopic Dermatitis
12%
Brodalumab
11%
Generalized Pustular Psoriasis
10%
Risankizumab
10%
Placebo
10%
Skin Diseases
9%
Guselkumab
9%
Clinical Practice
9%
Adalimumab
9%
Biological Treatment
9%
Phase II Trial
9%
Long-term Efficacy
9%
Biosimilar
8%
Europe
8%
Methotrexate
8%
Plaque Psoriasis
8%
Interleukin-23 (IL-23)
8%
Confidence Interval
7%
Long-term Safety
7%
Pooled Analysis
7%
Pustular Psoriasis
7%
Itch
6%
Network Meta-analysis
6%
Health-related Quality of Life
6%
Biological Agents
6%
Phase III Clinical Trial
6%
Immune-mediated Inflammatory Diseases
6%
Hidradenitis Suppurativa
5%
Systemic Treatment
5%
Biologic Therapy
5%
Comorbidity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Psoriasis Vulgaris
40%
Ustekinumab
27%
Biological Product
18%
Psoriatic Arthritis
17%
Diseases
16%
Clinical Trial
13%
Ixekizumab
13%
Secukinumab
12%
Etanercept
12%
Brodalumab
11%
Interleukin 17
11%
Placebo
10%
Adverse Event
10%
Methotrexate
9%
Risankizumab
8%
Atopic Dermatitis
8%
Adalimumab
7%
Guselkumab
6%
Pustular Psoriasis
6%
Inflammatory Disease
6%
Cytokine
5%
Infliximab
5%
Medicine and Dentistry
Psoriasis
74%
Psoriasis Vulgaris
28%
Psoriasis Area and Severity Index
17%
Quality of Life
17%
Diseases
17%
Biological Product
16%
Psoriatic Arthritis
13%
Ustekinumab
12%
Clinical Trial
11%
Generalized Pustular Psoriasis
11%
Dermatology Life Quality Index
11%
Ixekizumab
11%
Dermatology
11%
Etanercept
10%
Biosimilar
9%
Atopic Dermatitis
8%
Inflammatory Disorder
8%
Interleukin 17
7%
Adverse Event
7%
Comorbidity
6%
Adalimumab
6%
Pruritus
6%
Skin Disease
6%
Systemic Therapy
5%
Dermatosis
5%
Prevalence
5%
Cross Sectional Study
5%
Placebo
5%
Squamous Cell Carcinoma
5%
Risankizumab
5%
